

- overexpressing cell line. 2013 International Meeting on the Molecular Biology of Hepatitis B Viruses. 2013.10.20-23, Shanghai, China.
- 2) Tsukuda S, Watashi K, Iwamoto M, Suzuki R, Aizaki H, Kojima S, Wakita T. A Retinoid Derivative Inhibits Hepatitis B Virus Entry Mediated by NTCP. International Meeting on Molecular Biology of Hepatitis B Viruses. 2013.10.20-23. Shanghai, China.
- 3) Watashi K, Liang G, Iwamoto M, Marusawa H, Kitamura K, Muramatsu M, Suzuki R, Li J, Tong S, Tanaka Y, Murata K, Aizaki H, Wakita T. Interleukin-1 and tumor necrosis factor- α trigger restriction of hepatitis B virus infection via a cytidine deaminase AID. 2013 International Meeting on Molecular Biology of Hepatitis B viruses, 2013.10.20-23. Shanghai, China.
- 4) Fujimoto A, Aizaki H, Matsuda M, Watanabe N, Watashi K, Suzuki R, Suzuki T, Miyamura T, Wakita T, Dynamics of the cellular metabolome during hepatitis C virus infection: Regulation of the lipoprotein metabolisms by hepatic lipase, 20th International Symposium on Hepatitis C Virus and Related Viruses, Melbourne, Australia, 2013.10.6-10.
- 5) Nakajima S, Watashi K, Kamisuki S, Takemoto K, Suzuki R, Aizaki H, Sugawara F, Wakita T, Identification of a natural product inhibiting the transcriptional activity of liver X receptor and reducing the production of infectious HCV, 20th International Symposium on Hepatitis C Virus and Related Viruses, Melbourne, Australia, 2013.10.6-10.
- 6) Nakajima S, Watashi K, Kamisuki S, Takemoto K, Suzuki R, Aizaki H, Sugawara F, Wakita T, Analysis of bioactivity of fungal-derived natural products based on a virus infection system, The 2nd International Symposium on Chemical Biology of Natural Products: Target ID and Regulation of Bioactivity, Yokohama, 2013.10.28-29.
- 7) Suzuki R, Konishi E, Ishikawa T, Matsuda M, Watashi K, Aizaki H, Takasaki T, Wakita T. Production of single-round infectious chimeric flaviviruses with a DNA-based Japanese encephalitis virus replicon. Keystone Symposia, Positive Strand RNA Viruses, Boston, U.S.A. 2013.4.28-5.3
- 8) Aizaki H, Dynamic metabolomics change in HCV-infected cells, The 2013 Italy-Japan Liver Workshop "Hepatitis, Steatosis and Hepatocellular Carcinoma: molecular basis and clinical links", Italy 2013.10.20-21.
- 9) Aizaki H, Watanabe N, Aoyagi H, Hmwe SS, Watashi K, Suzuki R, Kojima S, Matsuura T, Wake K, Miyamura T, Suzuki T, Wakita T, Hepatitis C virus RNA replication in human stellate cells regulates gene expression of extracellular matrix-related molecules, International Symposium on Cells of the Hepatic Sinusoid, Osaka, 2013.9.23-25.
- 10) Sakata K, Hara M, Terada T, Watanabe N, Yaguchi S, Matsumoto M, Shirouzu M, Yokoyama S, Miyazawa K, Aizaki H, Suzuki T, Wakita T, Kojima S' HCV NS3 protease plus TNF- α promotes liver fibrosis via stimulating expression and activation of TGF- β type I receptor, 第20回肝細胞研究会, Osaka, 2013.9.26-27.
- 11) Aoyagi H, Aizaki H, Matsumoto Y, Matsuda M, Hmwe SS, Watanabe N, Watashi K, Suzuki R, Ichinose S, Matsuura T, Suzuki T,

- Wake K, Miyamura T, Wakita T. Antiviral activity of glycyrrhizin against hepatitis C virus in vitro, The 12th Awaji international forum on infection and immunity, 2013. 9.10-13.
- 12) Nagamori S, Aizaki H, Matsumoto Y, Isozumi N, Wiriyasermkul P, Matsuura T, Kanai Y, Comprehensive and comparative proteomics reveals alterations of metabolomics between monolayer and three-dimensional cell cultures. 12th Human Proteome Organization World Congress 2013. 9.14-18. Yokohama.
- 13) Aoyagi H, Aizaki H, Matsumoto Y, Matsuda M, Hmwe SS, Watanabe N, Watashi K, Suzuki R, Ichinose S, Matsuura T, Suzuki T, Wake K, Miyamura T, Wakita T. Regulation of Hepatitis C virus (HCV) release by phospholipase A2 and autophagy -Antiviral Activity of Glycyrrhizin against HCV, 日本分子生物学会第36回年会, 2013年12月3-6日, 神戸.
- 14) 鈴木亮介、石川知弘、小西英二、嵯峨涼平、松田麻未、渡士幸一、相崎英樹、高崎智彦、脇田隆字. プラスミドトランスフェクションによるトランスパッケージング型1回感染性フラビウイルス産生系の確立. 日本分子生物学会第36回年会, 2013年12月3-6日, 神戸.
- 15) 松田麻未、斎藤憲司、鈴木亮介、佐藤充、鐘ヶ江裕美、渡士幸一、相崎英樹、千葉丈、斎藤泉、脇田隆字、鈴木哲朗. 細胞内発現抗体 (イントラボディ) によるC型肝炎ウイルスの増殖抑制. 日本ウイルス学会第61回学術集会, 2013年11月10-12日, 神戸.
- 16) 鈴木亮介、小西英二、石川知弘、嵯峨涼平、松田麻未、渡士幸一、相崎英樹、高崎智彦、脇田隆字. 日本脳炎ウイルスレプリコンを用いたトランスパッケージング型1回感染性フラビウイルス粒子産生系の開発. 日本ウイルス学会第61回学術集会, 2013年11月10-12日, 神戸.
- 17) 青柳東代、相崎英樹、藤本陽、松本喜弘、松田麻未、Su Su Hmwe、渡邊則幸、渡士幸一、鈴木亮介、市野瀬志津子、松浦知和、鈴木哲朗、和氣健二郎、宮村達男、脇田隆字. Phospholipase A2およびAutophagyによるC型肝炎ウイルス(HCV)分泌過程の制御 - グリチルリチンによる抗HCV作用-、日本ウイルス学会第61回学術集会, 2013年11月10-12日, 神戸.
- 18) 藤本陽、相崎英樹、松田麻未、渡邊則幸、渡士幸一、鈴木亮介、鈴木哲朗、宮村達男、脇田隆字, C型肝炎ウイルス感染による宿主細胞の脂質代謝変化とHepatic Lipase発現制御、日本ウイルス学会第61回学術集会, 2013年11月10-12日, 神戸.
- 19) 内田奈々子、渡士幸一、中嶋 翔、岩本将士、鈴木亮介、相崎英樹、千葉 丈、脇田隆字, C型肝炎ウイルス分泌過程はphospholipase Dが関わる膜輸送により制御される, 日本ウイルス学会第61回学術集会, 2013年11月10-12日, 神戸.
- 20) 九十田千子、渡士幸一、岩本将士、鈴木亮介、相崎英樹、小嶋聡一、脇田隆字、B型肝炎ウイルス侵入阻害剤の同定およびそのNTCPを介した感染阻害機構の解明、日本ウイルス学会第61回学術集会, 2013年11月10-12日, 神戸.
- 21) 岩本将士、渡士幸一、九十田千子、Hussein Hassan Aly、鈴木亮介、相崎英樹、小祝 修、楠原洋之、脇田隆字: ヒトNTCP安定発現細胞株におけるB型肝炎ウイルス侵入機構の解析. 日本ウイルス学会第61回学術集会, 2013年11月10-12日, 神戸.
- 22) 渡邊則幸、伊達朋子、相崎英樹、脇田隆字: エンベロープペプチドを用いたHCV感染に重要なアミノ酸領域の探索, 日本ウイルス学会第61回学術集会, 2013年11月10-12日, 神戸.
- 23) 後藤耕司、相崎英樹、渡邊則幸、渡士幸一、鈴木亮介、山越智、四柳宏、森屋恭爾、小池和彦、鈴木哲朗、宮村達男、脇田隆字, C型肝炎ウイルスNS5A結合タンパク質ELAVL1のウイルス複製・翻訳スイッチング機構の解析, 日本ウイ

ルス学会第61回学術集会, 2013年11月10-12日,
神戸.

24) 渡士幸一、Guoxin Liang、岩本将士、丸澤
宏之、喜多村晃一、村松正道、鈴木亮介、相崎
英樹、脇田隆宇、IL-1/TNF α によるシチジнде
アミナーゼAID誘導を介したB型肝炎ウイルス感
染排除機構、日本ウイルス学会第61回学術集会,
2013年11月10-12日, 神戸.

25) 中嶋翔、渡士幸一、紙透伸治、竹本
健二、鈴木亮介、相崎英樹、菅原二三
男、脇田隆宇、Liver X Receptor 転写
活性および感染性C型肝炎ウイルス粒
子産生を阻害する天然有機化合物の同
定、第61回日本ウイルス学会学術集会、2013
年11月10-12日, 神戸.

26) 井戸田一朗、加藤康幸、青柳東代、相崎英
樹、脇田隆宇、当院で経験した、HIV陽性者
における急性C型肝炎の集団発生について、第27
回日本エイズ学会, 2013年11月20-22日, 熊本.

27) 相崎英樹、オートファジィにかかる治療戦
略2014、2013年2月15日, 東京.

H. 知的所有権の出願・取得状況

1. 特許取得

なし

2. 実用新案登録

なし

3. その他

なし

Ⅲ. 研究成果の刊行に関する一覧表

別紙 5

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
正木尚彦	第XVIII章 肝疾患診療に関する病診連携 1. 肝疾患診療連携拠点病院ならびに肝疾患診療連携ネットワーク. 第XIX章 肝疾患診療に関連する法律、制度 2. 肝炎対策基本法、3. 肝炎治療特別促進事業(医療費助成制度)	日本肝臓学会	肝臓専門医テキスト	南江堂	東京	2013	pp460-464、pp472-473、pp474-479
坂本穰、榎本信幸	慢性肝炎・肝硬変(C型)	一瀬雅夫、岡政志、持田智	治療過程で一目でわかる消化器薬物療法 STEP 1・2・3	メジカルビュー社	東京	2013	174-178
辰巳明久、坂本穰、榎本信幸	メタボ肝癌とファイブロスキャン	小俣政男	メタボ肝癌	アークメディア	東京	2013	163-168
坂本穰、榎本信幸	C型肝炎	浅香正博、菅野健太郎、千葉勉	カラー版消化器病学基礎と臨床	西村書店	東京	2013	1177-1188
吉岡健太郎	Wilson病	小俣政男、千葉勉	専門医のための消化器病学第2版	医学書院	東京	2013	399-401
吉岡健太郎	ヘモクロマトーシス	小俣政男、千葉勉	専門医のための消化器病学第2版	医学書院	東京	2013	401-403

吉岡健太郎	α_1 -アンチトリプシン欠乏症	矢崎義雄	内科学 (第10版)	朝倉書店	東京	2013	69-70
吉岡健太郎	肝腫大	矢崎義雄	内科学(第10版)	朝倉書店	東京	2013	1162-1163
川部直人、橋本千樹、原田雅生、有馬裕子、西川徹、吉岡健太郎	C型慢性肝炎における肝線維化推定と抗ウイルス治療	林紀夫	臨床消化器内科	日本メデイカルセンター	東京	2012	1467-1474
伊藤清顕、溝上雅史	全国調査からみたB型慢性肝炎の病態	佐田通夫 田中榮司 田中英夫 長尾由実子	コホート研究からみたウイルス性肝炎の解明	メディカルレビュー社	大阪府	2013	152-160
飯島尋子	画像検査を用いた新しい線維化診断法.	西口修平編	別冊医学のあゆみ 肝硬度 Update-肝硬変死の根絶をめざして.	医歯薬出版	東京	2013	43-8
飯島尋子, 田中弘教		日本肝臓学会編	肝臓専門医テキスト.	南江堂	東京	2013	
田中弘教, 飯島尋子	実地での留意点. 実地での留意点.	高山忠利, 泉並木編.	診療ガイドラインに沿った肝臓治療の要点と盲点.	文光堂	東京	2013	26-8
飯島尋子	Sonazoidの特性.	工藤正俊・國分茂博編	EOB-MRI/Sonazoid超音波による肝臓の診断と治療.	医学書院	東京	2013	202-4
田中弘教, 飯島尋子	肝臓のスクリーニングや確定診断で造影エコーはどのように使うのが効果的でしょうか?.	池田健次編	肝臓診療Q&A.	中外医学社	東京	2013	48-50

飯島尋子, 山平正浩	エラストグラフィ・画像診断.	竹井謙之・竹原徹郎・持田智編.	Hepatology Practice第2巻 NASH・アルコール性肝障害の診療を極める	文光堂	東京	2013	141-5
相崎英樹	HCV感染と代謝異常(脂質・エネルギー)		医学のあゆみ	医歯薬出版株式会社	東京	2013	245;666-667

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
正木尚彦	ウイルス肝炎に関する国の対策事業、公費助成や受診勧奨など. 特集 ウイルス肝炎の新展開	診断と治療	101(9)	1375-1380	2013
<u>Kudo M</u>	Advances in Liver Fibrosis Imaging and Hepatocellular Carcinoma: Update in 2013.	Oncology	84	1-2	2013
Fujimoto K, Kato M, <u>Kudo M</u> , Yada N, Shiina T, Ueshima K, Yamada Y, Ishida T, Azuma M, Ymasaki M, Yamamoto K, Hayashi N, Takehara T	Novel image analysis method using ultrasound elastography for non-invasive evaluation of hepatic fibrosis in patients with chronic hepatitis C.	Oncology	84	3-12	2013
Yada N, Morikawa H, Fujimoto K, Kato M, Kawada N, <u>Kudo M</u>	Assessment of liver fibrosis with real-time tissue elastography in chronic viral hepatitis.	Oncology	84	13-20	2013
<u>Kudo M</u> , Matsui O, Sakamoto M, Kitao A, Kim T, Ariizumi S, Ichikawa T, Kobayashi S, Imai Y, Izumi N, Fujinaga Y, Aii S	Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA MRI) in the	Oncology	84	21-27	2013

	management of hepatocellular carcinoma: Consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan.				
Inoue T, <u>Kudo M</u> , Hatanaka K, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Minami Y, Sakurai T, Ueshima k, Nishida N	Usefulness of contrast-enhanced ultrasonography to evaluate the post treatment responses of radiofrequency ablation for hepatocellular carcinoma; comparison with dynamic CT.	Oncology	84	51-57	2013
Minami Y, <u>Kudo M</u>	Therapeutic response assessment of transcatheter arterial chemoembolization for hepatocellular carcinoma: US, CT and MRI.	Oncology	84	58-63	2013
Minata M, Harada K, <u>Kudo M</u> , Ikai I, Nishida N	The prognostic value of vascular endothelial growth factor in hepatocellular carcinoma for predicting metastasis after curative resection.	Oncology	84	75-81	2013
Nishida N, Arizumi T, Takita M, Nagai T, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Ida H, <u>Kudo M</u>	Quantification of tumor DNA in serum and vascular invasion of human hepatocellular carcinoma.	Oncology	84	82-87	2013
Minata M, <u>Kudo M</u> , Harada K, Ikai I, Nishida N	Expression of E-cadherin and vascular endothelial growth factor in non-cancerous liver is associated with recurrence of HCC after curative resection.	Oncology	84	88-92	2013
Nishida N, <u>Kudo M</u>	Recent advancements in comprehensive genetic analyses for human hepatocellular carcinoma.	Oncology	84	93-97	2013

Claudon M, Dietrich CF, Choi BI, Cosgrove DO, <u>Kudo M</u> , Nolsoe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX	Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver-update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS.	Ultrasound Med Biol	39	187-210	2013
Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, <u>Kudo M</u> , Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y, for the Liver Cancer Study Group of Japan.	Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey.	J Hepatol	58	724-729	2013
Sakurai T, <u>Kudo M</u> , Umemura A, He G, Elsharkawy AM, Seki E, Karin M	p38 α inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species.	Cancer Res	73	215-224	2013
Claudon M, Dietrich CF, Choi BI, Cosgrove DO, <u>Kudo M</u> , Nolsoe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu	Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver-update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS.	Ultraschall Med	34	11-29	2013

F, Solbiati L, Weskott HP, Xu HX					
Watanabe T, Yamashita K, Sakurai T, <u>Kudo M</u> , Shiokawa M, Uza N, Kadoma Y, Uchida K, Okazaki K, Chiba T	Toll-like receptor activation in basophils contributes to the development of IgG4-related disease.	J Gastroenterol	48	247-253	2013
Nagata Y, <u>Kudo M</u> , Nagai T, Watanabe T, Kawasaki M, Asakuma Y, Hagiwara S, Nishida N, Matsui S, Kashida H, Sakurai T	Heat shock protein 27 expression is inversely correlated with atrophic gastritis and intraepithelial neoplasia.	Digest Dis Sci	58	381-388	2013
Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, <u>Kudo M</u> , Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Ceng AL	Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC).	Liver Int	33	327-337	2013
Minami Y, <u>Kudo M</u>	Radiofrequency ablation of liver metastases from colorectal cancer: a literature review.	Gut Liver	7	1-6	2013
Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, Sakurai T, Haji S, Kanazawa K, Hidaka H, Iso Y, Kubota K, Shimada M, Utsunomiya T, Hirooka M, Hiasa Y, Toyoki Y, Hakamada K, Yasui K, Kumada T, Hidenori Toyoda, Sato S, Hisai H, Kuzuya T,	FGF3/FGF4 Amplification and Multiple lung Matastases in responders to sorafenib in hepatocellular carcinoma.	Hepatology	57	1407-1415	2013

Tsuchiya K, Izumi N, Arii S, Nishio K, <u>Kudo M</u>					
Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, Moriwaki H, Adachi K, Katsushima S, <u>Kudo M</u> , Takaguchi K, Hiasa Y, Chayama K, Yatsuhashi H, Oketani M, Kumada H	Inhibition of hepatocellular carcinoma by PegIFN α -2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study.	J Gastroenterol	48	382-390	2013
Takayasu K, Arii S, Sakamoto M, Matsuyama Y, <u>Kudo M</u> , Ichida T, Nakashima O, Matsui O, Izumi N, Kuroda Y, Kokudo N, Makuuchi M, Liver Cancer Study Group of Japan	Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3 cm.	Liver Int	33	762-770	2013
Hyodo T, Murakami T, Imai Y, Okada M, Hori M, Kagawa Y, Kogita S, Kumano S, <u>Kudo M</u> , Mochizuki T	Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma.	Radiology	266	480-490	2013
Hagiwara S, <u>Kudo M</u> , Osaki Y, Matsuo H, Inuzuka T, Matsumoto A, Tanaka E, Sakurai T, Ueshima K, Inoue T, Yada Y, Nishida N	Impact of peginterferon Alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B.	J Med Virol	85	987-95	2013
<u>Kudo M</u>	Early Hepatocellular Carcinoma: Definition and Diagnosis.	Liver Cancer	2(2)	69-72	2013

Matsui S, Kashida H, <u>Kudo M</u>	Senile systemic amyloidosis localized to the stomach.	Digest Endosc	25	468-469	2013
Mine H, Sakurai T, Kashida H, Matsui S, Nishida N, Nagai T, Hagiwara S, Watanabe T, <u>Kudo M</u>	Association of gankyrin and stemness factor expression in human colorectal cancer.	Dig Dis Sci	58	2337-2344	2013
Inaba Y, Kanai F, Aramaki T, Yamamoto T, Tanaka T, Yamakado K, Kaneko S, <u>Kudo M</u> , Imanaka K, Kora S, Nishida N, Kawai N, Seki H, Matsui O, Arioka H, Arai Y	A randomized phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolization.	Eur J Cancer	49	2832-2840	2013
Takayama M, Matsui S, Kawasaki M, Asakuma Y, Sakurai T, Kashida H, <u>Kudo M</u>	Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers.	World J Gastroenterol	19	5706-5712	2013
<u>Kudo M</u>	[Preface] Chronic liver diseases and hepatocellular carcinoma: update in 2013.	Digest Dis	31	405-407	2013
Nishida N, Iwamura S, Ida H, Hagiwara S, Kagioka Y, Minami Y, Maetani Y, Itoh K, <u>Kudo M</u>	Clinical and histological features of different types of Budd-Chiari syndrome: A Comparison of 4 cases.	Digest Dis	31	408-414	2013
Yada N, <u>Kudo M</u> , Chung H, Watanabe T	Autoimmune hepatitis and immunoglobulin G4-associated autoimmune Hepatitis.	Digest Dis	31	415-420	2013
Sugimoto K, Kim SR, Shamy AE, Imoto S, Ando K, Kim KI, Tanaka Y, Yano Y, Kim SK, Hasegawa Y, Fujinami A, Ohta M, Takashi H, Hotta H,	Factors of response to pegylated interferon/ribavirin combination therapy and mechanism of viral clearance.	Digest Dis	31	421-425	2013

Hayashi Y, <u>Kudo M</u>					
Kim SR, Shamy AE, Imoto S, Kim KI, Sugimoto K, Kim SK, Tanaka Y, Hatae T, Hasegawa Y, Fujinami A, Ohta M, Hotta H, <u>Kudo M</u>	Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotypes 2a and 2b and high viral load.	Digest Dis	31	426-433	2013
Sugimoto K, Kim SR, Shamy AE, Imoto S, Fujioka H, Kim KI, Tanaka Y, Yano Y, Kim SK, Hasegawa Y, Fujinami A, Ohta M, Hatae T, Hotta H, Hayashi Y, <u>Kudo M</u>	Outcome of double-filtration plasmapheresis plus IFN treatment in non-responders to pegylated IFN plus ribavirin combination therapy.	Digest Dis	31	434-439	2013
Sakurai T, <u>Kudo M</u> , Watanabe T, Itoh K, Higashitsuji H, Arizumi T, Inoue T, Hagiwara S, Ueshima K, Nishida N, Fukumoto M, Fujita J	Hypothermia Protects against Fulminant Hepatitis in Mice by Reducing Reactive Oxygen Species Production.	Digest Dis	31	440-446	2013
Nishida N, <u>Kudo M</u>	Oxidative stress and epigenetic instability in human hepatocarcinogenesis.	Digest Dis	31	447-453	2013
Kim SK, Marusawa H, Eso Y, Chiba T, <u>Kudo M</u>	Novel mouse models of hepatocarcinogenesis with stepwise accumulation of genetic alterations.	Digest Dis	31	454-458	2013
Nishida N, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, <u>Kudo M</u>	Reactive oxygen species induce epigenetic instability through the formation of 8-hydroxydeoxyguanosine in human hepatocarcinogenesis.	Digest Dis	31	459-466	2013

Tsuji N, Ishiguro S, Sasaki Y, <u>Kudo M</u>	CD-34 expression in noncancerous liver tissue predicts multicentric recurrence of hepatocellular carcinoma.	Digest Dis	31	467-471	2013
Inoue T, Hyodo T, Murakami T, Takayama Y, Nishie A, Higaki A, Korenaga K, Sakamoto A, Osaki Y, Aikata H, Chayama K, Suda T, Takano T, Miyoshi K, Koda M, Numata K, Tanaka H, Iijima H, Ochi H, Hirooka M, Imai Y, <u>Kudo M</u>	Hypovascular hepatic nodules showing hypointense on the hepatobiliary phase image of Gd-EOB-DTPA enhanced MRI to develop a hyper-vascular hepatocellular carcinoma: a nationwide retrospective study on their Natural course and Risk factors.	Digest Dis	31	472-479	2013
Minami Y, Hayaishi S, <u>Kudo M</u>	Radiofrequency ablation for hepatic malignancies: is the needle tract cauterization necessary for preventing iatrogenic bleeding?	Digest Dis	31	480-484	2013
Makino Y, Imai Y, Igura T, Kogita S, Sawai Y, Fukuda K, Hori M, <u>Kudo M</u> , Murakami T	Usefulness of the extracted-overlay function in CT/MR-ultrasonography fusion imaging for radiofrequency ablation of hepatocellular carcinoma.	Digest Dis	31	485-489	2013
<u>Kudo M</u> , Osaki Y, Matsunaga T, Kasugai H, Oka H, Seki T, the Osaka Liver Cancer Study Group	Hepatocellular carcinoma in Child-Pugh C cirrhosis: prognostic factors and survival benefit of nontransplant treatments.	Digest Dis	31	490-498	2013
<u>Kudo M</u>	Alpha-fetoprotein-L3: Useful or Useless for Hepatocellular Carcinoma?	Liver Cancer	2(3-4)	151-152	2013
Sakurai T, <u>Kudo M</u>	Molecular link between liver fibrosis and hepatocellular carcinoma.	Liver Cancer	2(3-4)	365-366	2013

Kudo M, Shiina T, Moriyasu F, Iijima H, Tateishi R, Yada N, Fujimoto K, Morikawa H, Hirooka M, Sumino Y, Kumada T	JSUM ultrasound elastography practice guidelines: liver.	J Med Ultrason	40	325-357	2013
Kagawa Y, Okada M, Yagyū Y, Kumano S, Kanemitsu M, Kudo M, Murakami T	Optimal scan timing of hepatic arterial-phase imaging of hypervascular hepatocellular carcinoma determined by multiphase fast CT imaging technique.	Acta Radiol	54	843-850	2013
Nouso K, Miyahara K, Uchida D, Kuwaki K, Izumi N, Omata M, Ichida T, Kudo M, Ku Y, Kokudo N, Sakamoto M, Nakashima O, Takayama T, Matsui O, Matsuyama Y, Yamamoto K, the Liver Cancer Study Group of Japan	Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan.	Brit J Cancer	109	1904-1907	2013
Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Lowenthal SP, Lanzaone S, Yang L, Lechuga MJ, Raymond E, for the SUN1170 HCC Study Group	Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.	J Clin Oncol	10; 31	4067-4075	2013
Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E,	Brivanib versus Sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized Phase 3	J Clin Oncol	1; 31	3517-3524	2013

Han KH, Paik SW, Avina JR, <u>Kudo M</u> , Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL	BRISK-FL study.				
Llovet JM, Decaens T, Raoul JL, Boucher E, <u>Kudo M</u> , Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc, JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW	Brivanib in patients with advanced hepatocellular carcinoma who failed or were intolerant to sorafenib: or for whom sorafenib failed results from the randomized phase 3 BRISK-PS study.	J Clin Oncol	1; 31	3509-3516	2013
Lencioni R, <u>Kudo M</u> , Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ	GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.	Int J Clin Pract		1-9	2013
Nishida N, <u>Kudo M</u> , Nishimura T, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Yokomichi N, Nagasaka T, Goel A	Unique association between global DNA hypomethylation and chromosomal alterations in human hepatocellular carcinoma.	Plos One	8(9)	e72312	2013
Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Nozaki Y, Nagata N,	Traditional but Not HIV-Related Factors Are Associated with Nonalcoholic Fatty Liver Disease	PLOS ONE	Volume 9	e87596	2014

Kikuchi Y, Yanase M, Oka S.	in Asian Patients with HIV-1 Infection.				
Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Matsuura K, Asahina Y, Nakagawa M, Watanabe M, <u>Sakamoto M</u> , Maekawa S, Tokunaga K, Mizokami M, Izumi N.	Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C	J Med Virol	85 (3)	449-458	2013
Miura M, Maekawa S, Takano S, Komatsu N, Tatsumi A, Asakawa Y, Shindo K, Amemiya F, Nakayama Y, Inoue T, <u>Sakamoto M</u> , Yamashita A, Moriishi K, Enomoto N.	Deep-Sequencing Analysis of the Association between the Quasispecies Nature of the Hepatitis C Virus Core Region and Disease Progression	J. Virol.	87	12541-12551	2013
<u>坂本穰</u> 、榎本信幸	C型肝炎治療における宿主因子とウイルス因子 - 実地診療での臨床応用のすすめかた	Medical Practice	30 (2)	323-328	2013
<u>坂本穰</u> 、榎本信幸	C型肝炎硬変における抗ウイルス療法	Modern physician	33 (4)	454-458	2013
<u>坂本穰</u> 、榎本信幸	ウイルス変異と宿主ゲノムからみたインターフェロン療法の治療成績と発癌リスクを考慮した新規治療法への展望	消化器内科	56 (4)	437-442	2013
<u>坂本穰</u> 、榎本信幸	発癌リスクと治療反応性を考慮したC型肝炎の最新治療	消化器内科	57 (3)	379-384	2013
<u>坂本穰</u> 、榎本信幸	C型肝炎診療 up-to-date、発癌リスクと新規治療法	診断と治療	101 (9)	1277-1282	2013

坂本穰、榎本信幸	C型肝炎の自然経過と発癌リスク	成人病と生活習慣病	43 (11)	1310-1315	2013
坂本穰、榎本信幸	C型肝炎ウイルスと治療	HIV感染症とAIDSの治療	4 (2)	55-59	2013
坂本穰、榎本信幸	プロテアーゼ阻害剤に対する耐性変異と意義	肝胆膵	67 (6)	893-898	2013
坂本穰、榎本信幸	B型肝炎のインターフェロン治療: sequential thrapy を含めて	Phama Medica	31 (12)	49-52	2013
Shirasaki T, Honda M, Shimakami T, Horii R, Yamashita T, Sakai Y, Sakai A, Okada H, Watanabe R, Murakami S, Yi M, Lemon SM, Kaneko S.	MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells.	J Virol	87	5720-86	2013
Spaniel C, Honda M, Selitsky SR, Yamane D, Shimakami T, Kaneko S, Lanford RE, Lemon SM.	microRNA-122 abundance in hepatocellular carcinoma and non-tumor liver tissue from Japanese patients with persistent HCV versus HBV infection.	PLoS One	8	e76867	2013
Honda M, Shirasaki T, Shimakami T, Sakai A, Horii R, Arai K, Yamashita T, Sakai Y, Yamashita T, Okada H, Murai K, Nakamura M, Mizukoshi E, Kaneko S.	Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin 28B genotypes.	Hepatology	in press	in press	2013

Posuwan N, Payungporn S, Tangkijvanich P, Ogawa S, Murakami S, Iijima S, Matsuura K, Shinkai N, <u>Watanabe T</u> , Poovorawan Y, Tanaka Y.	Genetic association of human leukocyte antigens with chronicity or resolution of hepatitis B infection in thai population.	PLoS One	9(1)	e86007	2014
Matsuura K, <u>Watanabe T</u> , and Tanaka Y.	Role of IL28B for chronic hepatitis C treatment toward personalized medicine.	J Gastroentero l Hepatol.	29(2)	241-9	2014
Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, <u>Watanabe T</u> , Tanaka Y.	Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.	Liver Int.	in press	doi: 10.1111/liv .12321. PMID: 24102823	2013
<u>Watanabe T</u> , Inoue T, Tanoue Y, Maekawa H, Hamada-Tsutsumi S, Yoshiba S, Tanaka Y.	Hepatitis C Virus Genotype 2 May Not Be Detected by the Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 1.0.	J Clin Microbiol.	51(12)	4275-4276	2013
Shinkai N, Matsuura K, Sugauchi F, <u>Watanabe T</u> , Murakami S, Iio E, Ogawa S, Nojiri S, Joh T, Tanaka Y.	Application of a Newly Developed High-Sensitivity HBsAg Chemiluminescent Enzyme Immunoassay for Hepatitis B Patients with HBsAg Seroclearance.	J Clin Microbiol	51	3484-3491	2013
Wong DK, <u>Watanabe T</u> , Tanaka Y, Seto WK, Lee CK, Fung J, Lin CK, Huang FY, Lai CL, Yuen MF.	Role of HLA-DP polymorphisms on chronicity and disease activity of hepatitis B infection in Southern Chinese.	PLoS One	8	e66920	2013
Arata S, Nozaki A, Takizawa K, Kondo M, Morimoto M, Numata K, Hayashi S, <u>Watanabe T</u> , Tanaka Y, Tanaka K.	Hepatic failure in pregnancy successfully treated by online hemodiafiltration: Chronic hepatitis B virus infection without viral genome mutation.	Hepatol Res	43(12)	1356-60	2013

吉岡健太郎、橋本千樹、川部直人、原田雅生、西川徹、市野直浩、刑部恵介	FibroScanを用いた治療後肝硬度変化の測定	肝胆膵	67(6)	1059-1064	2013
K. Hayashi, Y. Katano, H. Masuda, Y. Ishizu, T. Kuzuya, T. Honda, M. Ishigami, A. Itoh, Y. Hirooka, I. Nakano, T. Ishikawa, F. Urano, <u>K. Yoshioka</u> , H. Toyoda, T. Kumada and H. Goto	Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B	Hepatol Res	43(6)	580-8	2013
<u>K. Yoshioka</u>	What is the benefit of computer-assisted image analysis of liver fibrosis area?	J Gastroenterol	48(8)	996-7	2013
<u>K. Yoshioka</u>	How to adjust the inflammation-induced overestimation of liver fibrosis using transient elastography?	Hepatol Res	43(2)	182-4	2013
Tamaki Y, Nakade Y, Yamauchi T, Makino Y, Yokohama S, Okada M, Aso K, Kanamori H, Ohashi T, Sato K, Nakao H, Haneda M, <u>Yoneda M.</u>	Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis.	J Gastroenterol	48(4)	491-503	2013
Yotsuyanagi H, <u>Ito K</u> , Yamada N, Takahashi H, Okuse C, Yasuda K, Suzuki M, Moriya K, Mizokami M, Miyakawa Y, Koike K.	High Levels of Hepatitis B Virus After the Onset of Disease Lead to Chronic Infection in Patients With Acute Hepatitis B.	Clin Infect Dis	57(7)	935-42	2013
Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S,	A Serum A”sweet-doughnut” protein facilitates fibrosis evaluation and therapy	Sci Rep	3	1065	2013